ABBV:NYE-AbbVie Inc.

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing

USD 78.69

Change

0.00 (0.00)%

Market Cap

USD 96.34B

Volume

4.08M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AbbVie Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

N/A

USD 356.57B
PFE Pfizer Inc.

N/A

USD 235.74B
MRK Merck & Company Inc. (new)

N/A

USD 205.28B
NVS Novartis AG

N/A

USD 202.33B
LLY.WD Eli Lilly and Company When Dis..

N/A

USD 130.66B
AZN Astrazeneca PLC

N/A

USD 105.49B
LLY Eli Lilly and Company

N/A

USD 105.13B
GSK GlaxoSmithKline PLC

N/A

USD 100.81B
BMY Bristol-Myers Squibb Company

N/A

USD 72.41B
TAK Takeda Pharmaceutical Company ..

N/A

USD 55.32B

ETFs Containing ABBV

ACT AdvisorShares Vice ETF 5.36 % 0.75 %

N/A

USD 0.01B
WBIY WBI Power Factor High Div.. 4.76 % 0.70 %

N/A

USD 0.10B
RDIV Invesco Exchange-Traded F.. 4.60 % 0.39 %

N/A

USD 1.82B
PJP Invesco Dynamic Pharmaceu.. 4.49 % 0.57 %

N/A

USD 0.40B
FDL First Trust Morningstar 4.18 % 0.45 %

N/A

USD 1.69B
PKW Invesco BuyBack Achievers.. 4.04 % 0.63 %

N/A

USD 1.17B
MPCT iShares MSCI Global Impac.. 3.70 % 0.49 %

N/A

USD 0.04B
ZWH:CA BMO US High Dividend Cove.. 3.67 % 0.71 %

N/A

CAD 0.76B
ZWH.U:CA BMO US High Dividend Cove.. 3.67 % 0.72 %

N/A

CAD 0.07B
SDG iShares MSCI Global Impac.. 3.47 % 0.49 %

N/A

USD 0.05B
BIBL Inspire 100 3.12 % 0.35 %

N/A

USD 0.06B
XLV SPDR Select Sector Fund -.. 3.09 % 0.13 %

N/A

USD 17.74B
VHT Vanguard Health Care 2.94 % 0.10 %

N/A

USD 9.21B
IYH iShares U.S. Healthcare 2.86 % 0.43 %

N/A

USD 2.16B
FHLC Fidelity MSCI Health Care.. 2.61 % 0.08 %

N/A

USD 1.57B
DQD:CA WisdomTree U.S. Quality D.. 2.32 % 0.49 %

N/A

CAD 0.03B
DGRW WisdomTree U.S. Quality D.. 2.32 % 0.28 %

N/A

USD 2.77B
DGR:CA WisdomTree U.S. Quality D.. 2.32 % 0.43 %

N/A

CAD 0.02B
DGR.B:CA WisdomTree U.S. Quality D.. 2.32 % 0.37 %

N/A

CAD 0.07B
RNDV First Trust US Equity Div.. 2.07 % 0.50 %

N/A

USD 5.46M
QDEF FlexShares Quality Divide.. 2.06 % 0.37 %

N/A

USD 0.41B
CUD:CA iShares US Dividend Growe.. 2.01 % 0.66 %

N/A

CAD 0.55B
QDF FlexShares Quality Divide.. 1.97 % 0.37 %

N/A

USD 1.73B
SDY SPDR S&P Dividend 1.89 % 0.35 %

N/A

USD 18.95B
ZDY:CA BMO US Dividend ETF 1.77 % 0.32 %

N/A

CAD 1.34B
ZDY.U:CA BMO US Dividend ETF 1.77 % 0.33 %

N/A

CAD 0.04B
CAPS:CA Evolve Active US Core Equ.. 1.51 % 0.96 %

N/A

CAD 3.67M
CAPS.B:CA Evolve Active US Core Equ.. 1.51 % 0.96 %

N/A

CAD 2.21M
CAPS.U:CA Evolve Active US Core Equ.. 1.45 % 0.00 %

N/A

CAD 0.99M
CUD.A:CA iShares US Dividend Growe.. 1.42 % 1.48 %

N/A

CAD 0.03B
USDY Pacific Global US Equity .. 1.36 % 0.00 %

N/A

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.64% 19% F 7% F
Dividend Return 2.32% 82% B- 66% D
Total Return -12.32% 19% F 8% F
Trailing 12 Months  
Capital Gain -20.97% 43% F 19% F
Dividend Return 4.08% 83% B 61% D-
Total Return -16.89% 38% F 21% F
Trailing 5 Years  
Capital Gain 45.72% 88% B+ 81% B-
Dividend Return 24.87% 100% A+ 74% C
Total Return 70.59% 88% B+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 12.55% 86% B 86% B
Dividend Return 16.37% 90% A- 87% B+
Total Return 3.82% 87% B+ 66% D
Risk Return Profile  
Volatility (Standard Deviation) 27.84% 29% F 20% F
Risk Adjusted Return 58.81% 81% B- 66% D
Market Capitalization 96.34B 85% B 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.30 41% F 29% F
Price/Book Ratio -39.74 100% A+ 99% A+
Price / Cash Flow Ratio 2.31 52% F 52% F
Price/Free Cash Flow Ratio 9.32 67% D+ 54% F
Management Effectiveness  
Return on Equity -203.31% 4% F 1% F
Return on Invested Capital 20.96% 81% B- 85% B
Return on Assets 8.87% 81% B- 85% B
Debt to Equity Ratio -478.75% 100% A+ 98% A+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative Book Value

The company has negative book value.